Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis

医学 斯科拉德 乌斯特基努马 湿疹面积及严重程度指数 安慰剂 特应性皮炎 塞库金单抗 皮肤科生活质量指数 随机对照试验 内科学 杜皮鲁玛 不利影响 皮肤病科 银屑病 英夫利昔单抗 银屑病性关节炎 病理 替代医学 疾病
作者
Igor Snast,Ofer Reiter,Emmilia Hodak,Rivka Friedland,Daniel Mimouni,Yael A. Leshem
出处
期刊:American Journal of Clinical Dermatology [Adis, Springer Healthcare]
卷期号:19 (2): 145-165 被引量:81
标识
DOI:10.1007/s40257-017-0324-7
摘要

Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for improved AD therapeutics.The aim of this study was to evaluate the efficacy and safety of biologic agents in AD.A systematic review and meta-analysis of studies evaluating AD patients treated with biologics was performed. The primary outcome was the Eczema Area and Severity Index (EASI)-75 response, while secondary outcomes were SCOring Atopic Dermatitis (SCORAD)-75, EASI-50, SCORAD-50, Investigator Global Assessment 0/1 responses, change in responses from baseline, and adverse events.We included 13 randomized controlled trials (RCTs) and 10 observational studies evaluating nine biologics. High-quality evidence was available for dupilumab, nemolizumab and ustekinumab. Pooling five studies, at weeks 12-16 dupilumab 300 mg every week to every 2 weeks achieved EASI-75 responses of 55%, superior to placebo [relative risk (RR) 3.3, 95% confidence interval (CI) 2.9-3.6]. Nemolizumab had similar EASI-75 responses as placebo, but significantly improved pruritus. In online reports, lebrikizumab demonstrated superior EASI-50 responses versus placebo (RR 1.3, 95% CI 1.04-1.7), while tralokinumab had superior SCORAD-50 responses versus placebo, with borderline significance (RR 1.7, 95% CI 0.97-3.1). In two RCTs each, omalizumab and ustekinumab were comparable with placebo, while antithymic stromal lymphopoietin receptor, infliximab, and rituximab lacked adequate evidence of efficacy. All medications had a comparable safety profile to placebo.Lack of RCTs and the use of variable outcome measures limited conclusions.Dupilumab is currently the only biologic with robust evidence of efficacy in AD. Nemolizumab, lebrikizumab, and tralokinumab show promise but further data are needed. Longer follow-up and larger studies will establish their safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
房源发布了新的文献求助10
1秒前
Ava的应助被xiaoputaor采纳,获得10
1秒前
1秒前
2秒前
2秒前
2秒前
xinglin发布了新的文献求助10
3秒前
Rosemarry完成签到,获得积分10
3秒前
3秒前
Yuan88发布了新的文献求助10
3秒前
4秒前
达不溜关注了科研通微信公众号
4秒前
5秒前
5秒前
5秒前
molihuakai的应助被yjt采纳,获得10
5秒前
5秒前
cxting完成签到 ,获得积分10
6秒前
7秒前
阎罗恶煞发布了新的文献求助100
8秒前
8秒前
8秒前
8秒前
8秒前
大个的应助被drizzle采纳,获得10
9秒前
9秒前
9秒前
9秒前
123发布了新的文献求助10
10秒前
在水一方的应助被纪十三采纳,获得30
10秒前
地雷完成签到 ,获得积分10
10秒前
cjk关注了科研通微信公众号
11秒前
11秒前
12秒前
12秒前
山海不远发布了新的文献求助10
12秒前
12秒前
跳跃靖发布了新的文献求助10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184220
求助须知:如何正确求助?哪些是违规求助? 9573266
关于积分的说明 21830447
捐赠科研通 7781246
什么是DOI,文献DOI怎么找? 3434248
关于科研通互助平台的介绍 2558373
邀请新用户注册赠送积分活动 2480784